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We would like to thank Professor Parsons for his interest
and comments concerning our manuscript ‘‘Cytotoxicity of
Oxycodone and Morphine in Human Neuroblastoma and
Mouse Motoneuronal Cells: A Comparative Approach’’
[1]. We totally agree with Parsons that the choice of
appropriate cell model is of paramount importance in
in vitro drug toxicity testing [2]. Moreover, using at least
two cell lines and two toxicity assays is endorsed in order
to have more accurate and relevant interpretation of drug
toxicity for clinical use. In our study, we have used the SH-
SY5Y and NSC-34 cell lines, and 3-(4,5-dimethylthiazole-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) and resa-
zurin reduction assays, all of which are commonly used for
assessing the toxicity of different compounds. In the pre-
sent study, the toxicity of both compounds, oxycodone and
morphine, appeared to be similar in both cell lines and both
assays.
The main focus of the letter to the editor by Parsons is
that the two cell lines used in our study were not differ-
entiated prior to neurotoxicity testing. Use of transformed
cell lines is a widely used approach in scientific literature
to get ‘quick answers for easy questions’. We are not
claiming that the cell models used were the most optimal.
However, these two cell lines, the SH-SY5Y and NSC-34
cell lines, are widely used and were available on our
campus. Moreover, we have expertise for resazurin and
classical MTT tests, both commonly accepted as accurate
methods in this kind of evaluation. In this study, the first
endpoint tested was cell viability. Both cell lines resulted in
a comparable outcome for ‘toxic’ concentrations, which
were well above those reached in clinical work. Therefore,
further studies were carried out with SH-SY5Y cells only,
which are routinely used in in vitro neurotoxic studies.
Based on the PubMed search,[620 studies targeting neu-
rotoxicity as an endpoint have been carried out with SH-
SY5Y cells thus far. Our proof-of-concept data should be
considered as preliminary ‘kick-offs’ for further studies
with additional cell signaling, ‘omics’, or any other more
specific endpoints. For more conclusive studies, more rel-
evant differentiated cell lines of human origin should be
used as proposed by Parsons.
We agree with Parsons that the results based on
in vitro cell models may not replicate in vivo phenotypes
[2], and thus, as we wrote, ideally a complete roster of
histologic, physiologic, and behavioral testing should be
performed on spinal drugs in two or more animal species,
followed by safety trials in humans prior to widespread
clinical use [1].
In conclusion, the results of our study [1] should be
considered as preliminary data on the neurotoxicity of
epidural oxycodone. The data support our clinical experi-
ence with several decades of epidural infusion of oxy-
codone in palliative care and our study hypothesis that
neurotoxicity of oxycodone may not be inferior to that of
morphine. However, further studies and close follow-up of
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patients are required for epidural pain management in the
most vulnerable patient groups.
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